Form 4: Armata Pharmaceuticals Director Robin Kramer Reports Stock Option Grants

Director Robin Kramer reports acquisition of stock options in Armata Pharmaceuticals.

Summary

• Robin Kramer, a director of Armata Pharmaceuticals, reported the acquisition of stock options on March 14, 2024.
• Kramer acquired 39,666 stock options that will vest upon the company's 2024 annual shareholders meeting, contingent on continuous service.
• An additional 54,343 stock options were acquired, vesting 50% on March 14, 2025, and 50% on March 14, 2026, also subject to continuous service.
• The exercise price for all options is $3.38.
• Following the reported transactions, Kramer directly owns 94,009 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a standard practice. There are no explicit positive or negative indicators.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the director's continuous service, suggesting an expectation of continued involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedules (annual shareholder meeting and staggered vesting over two years) are typical structures used to incentivize long-term commitment.
• Comparable companies such as BioCryst Pharmaceuticals or Idera Pharmaceuticals also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grants align the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Next Steps

• The options will vest according to the specified schedule, contingent on the director's continued service.

Key Dates